Faeth Therapeutics (4070) AI Stock Analysis

Faeth Therapeutics

(Frankfurt:4070)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageMinimal debt relative to equity reduces solvency pressure and interest-related constraints while preserving financial flexibility. This gives Faeth more capacity to fund development activities and manage setbacks, although it does not by itself create revenue or eliminate the need for future financing.

Negative Factors

No revenue tractionThe absence of sustained revenue indicates that Faeth has not yet established a commercial income stream from its therapeutic programs. This keeps the business dependent on development progress and external capital, increasing execution risk until candidates can generate meaningful recurring revenue.

Faeth Therapeutics (4070) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 481.80M
Dividend Yield: ―
Average Volume (3M): 98
Price to Earnings (P/E): -0.1
Beta (1Y): 0.78
Revenue Growth: ―
EPS Growth: -515.67%
Country: Germany
Employees: 29
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Faeth Therapeutics Business Overview & Revenue Model

Company Description

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-...

Faeth Therapeutics Risk Analysis

Faeth Therapeutics disclosed 82 risk factors in its most recent earnings report. Faeth Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. This conclusion is driven by contingent cash settlement provisions of our Series B Preferred Stock and is not based on insufficiency of our cash resources to fund currently planned operations.Q1, 2026

Faeth Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4070 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLRB	48Neutral	$11.39M	-0.26	-165.71%	―	―	77.68%
COCP	45Neutral	$19.17M	-1.24	-207.47%	―	―	38.55%
BOLT	40Underperform	$12.69M	-0.41	-126.23%	―	12.79%	37.93%
BRTX	38Underperform	$1.93M	-0.06	-423.84%	―	-8.47%	25.62%

* Healthcare Sector Average

Performance Comparison

DE:4070 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4070	Faeth Therapeutics, Inc.	16.30	10.30	171.67%
CLRB	Cellectar Biosciences Inc	1.22	-2.13	-63.58%
COCP	Cocrystal Pharma	1.06	0.03	2.91%
BRTX	Biorestorative Therapies, Inc.	1.48	-27.72	-94.93%
BOLT	Bolt Biotherapeutics, Inc.	6.24	1.20	23.81%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Faeth Therapeutics AI Stock Analysis